Welcome to our dedicated page for Biofrontera SEC filings (Ticker: BFRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biofrontera Inc. (NASDAQ: BFRI) SEC filings page provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Biofrontera is a U.S.-based biopharmaceutical company focused on dermatology and photodynamic therapy (PDT), commercializing Ameluz® and the RhodoLED® lamp series for actinic keratoses and developing additional indications such as superficial basal cell carcinoma and acne vulgaris.
Through its current and periodic reports, investors can review how Biofrontera describes its business, risk factors and financial condition. Form 8-K filings document material events, including quarterly financial results, strategic transactions with Biofrontera AG to acquire all U.S. rights to Ameluz® and RhodoLED®, private placements of Series C and Series D convertible preferred stock, and the divestiture of the Xepi® antibiotic cream license. Other 8-Ks detail Nasdaq listing compliance notices and stockholder meeting outcomes.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) typically include information on revenues from dermatology products, operating expenses, liquidity, and discussions of clinical and regulatory progress for Ameluz®-PDT. These filings also outline the company’s reliance on product sales, competition in dermatology, intellectual property matters, and other risks relevant to its PDT-focused business model.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as revenue trends, changes in earnout structures, capital raises, and outcomes of clinical and regulatory milestones. Investors can also use this page to monitor Form 4 insider transaction reports, as well as proxy and registration statements that discuss governance, capital structure and preferred stock offerings.
By combining real-time EDGAR updates with AI-generated insights, this page offers a structured view of Biofrontera’s regulatory history, financial reporting, and material corporate events tied to its dermatology and photodynamic therapy strategy.
George Patrick Jones, listed at 120 Presidential Way, Suite 330, Woburn MA 01801, filed an initial Form 3 for Biofrontera Inc. (BFRI) reporting an event date of 08/25/2025. He is identified as a Director and Chief Commercial Officer. The filing states no securities are beneficially owned. The form was executed by an attorney-in-fact, Daniel Hakansson, on 09/16/2025.
Kevin D. Weber, a director of Biofrontera Inc. (BFRI), received a grant of employee stock options on 07/22/2025. The grant comprises 20,000 options with an exercise price of $1.00 per share and an expiration date listed as 07/22/2035. The form shows 20,000 common shares beneficially owned following the reported transaction and indicates ownership is held directly. The filer states the option "vests in twelve equal monthly installments beginning on August 22, 2025." The filing was signed on behalf of Mr. Weber by an attorney-in-fact on 09/16/2025. Other options with different terms are not included.
Hermann Luebbert, CEO & Chairman and director of Biofrontera Inc. (BFRI), reported equity awards and option grants during 2024–2025. The Form 4 shows a 07/22/2025 grant of 125,000 restricted stock units (RSUs) and a contemporaneous employee stock option to buy 125,000 shares at $1.00 (exercise through 07/22/2035). On 09/10/2025 a transaction coded "M" reports acquisition of 137,500 shares (via conversion or settlement of RSUs). The RSUs convert one-for-one into common stock and were received for no consideration; some RSUs vest in two equal yearly installments beginning July 22, 2026, and other RSUs granted July 12, 2024 vest beginning July 12, 2025. Vested RSUs may be settled in shares, cash, or a combination within 60 days of vesting. The reporting was signed by an attorney-in-fact on 09/16/2025.
Biofrontera Inc. reported insider transactions by Chief Financial Officer Eugene Frederick Leffler III showing equity awards and issuances of common stock-equivalent instruments. The filing discloses that Mr. Leffler received 62,500 restricted stock units and an option to purchase 62,500 shares at $1.00 on 07/22/2025, and an additional 87,500 restricted stock units reported on 09/10/2025. The restricted stock units convert one-for-one into common shares when vested.
The 62,500 RSUs granted on 07/22/2025 vest in two equal annual installments beginning July 22, 2026, with settlement (shares, cash, or combination) within 60 days of vesting at the company's discretion. The option vests in two equal annual installments beginning January 22, 2026, and expires on July 22, 2035. The 87,500 RSUs reported on 09/10/2025 were recorded via transaction code M and are listed as acquired, leaving the reporting person with 87,500 shares following that transaction.
Heikki Lanckriet, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to purchase 20,000 shares of common stock at an exercise price of $1.00 per share. The option shows an exercise/vesting reference date of 07/22/2025 and an expiration date of 07/22/2035. The filing states the option vests in twelve equal monthly installments beginning on August 22, 2025. Following the grant, the report lists 20,000 underlying shares as beneficially owned by Mr. Lanckriet on a direct basis.
Beth J. Hoffman, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to buy 20,000 shares of common stock at an exercise price of $1.00 per share. The option becomes exercisable in monthly installments beginning August 22, 2025 and vests over twelve equal monthly installments; the option expires on July 22, 2035. The Form 4 was signed by an attorney-in-fact on September 16, 2025. The filing reports the grant as a direct beneficial ownership of 20,000 underlying shares.
John J. Borer III, a director of Biofrontera Inc. (BFRI), reported a non-derivative change dated 07/22/2025. The filing shows an employee stock option transaction: 20,000 options with a $1 exercise price, exercisable on 07/22/2025 and expiring on 07/22/2035. Following the reported transaction, 20,000 shares of common stock are shown as beneficially owned directly. The option vests in twelve equal monthly installments beginning 08/22/2025. The form is signed by Daniel Hakansson as attorney-in-fact for Mr. Borer on 09/16/2025.